About Us

A NEW APPROACH TO FIGHT NEURODEGENERATIVE DISEASES

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population.

Led by founder David Elmaleh, Ph.D., a renowned and prolific inventor and molecular scientist, the AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably. The company’s license agreements and close relationships with three separate laboratories at Harvard University and Massachusetts General Hospital (MGH):

  • Rudy Tanzi, Ph.D.: Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at MGH,
  • Brad Hyman, M.D., Ph.D.: John B. Penny Professor of Neurology at Harvard Medical School and Director of the Massachusetts Alzheimer Disease Research Center and Memory Disorder Unit at MGH, and
  • Merit Cudkowicz, M.D., M.Sc.: Chief of Neurology at MGH, Director of Neurological Clinical Research Institute and the Julieanne Dorn Professor of Neurology at Harvard Medical School, Co-Founder and Former Co-chair of Northeast ALS Consortium,

have enabled a strong patent portfolio, collaborative research, and access to some of the leading pioneers in neuroscience.

Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease is now fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative diseases.

AZTherapies is a private company headquartered in Boston, Massachusetts.

AZTherapies At A Glance

01

BREAKTHROUGH SCIENCE

Neuroinflammatory mechanism that changes the activation state of microglial brain immune cells from an aggressive, pro-inflammatory state to an anti-inflammatory, neuroprotective state.
02

EXECUTION

Advanced Phase 3 trial of a novel drug combination in early Alzheimer’s Disease. Completed two Phase 1 studies in healthy and healthy and AD patients. Approved IND for P2 study in post-ischemic stroke. Next-generation compound pre-IND.
03

PATENT PORTFOLIO

More than 100 patents & pending applications claiming novel compositions of matter, formulation, manufacturing and device/delivery for numerous neurodegenerative and other indications.
04

PIPELINE

Multiple follow-on programs with potential to treat and slow the progression of neurodegenerative diseases, while improving the quality of life of the aging population.
05

LEADERSHIP

World class management team, Board of Directors, Scientific Advisory Board, and Business Advisory Board.

Leadership

photo of David Elmaleh

SCIENTIFIC FOUNDER, CHAIRMAN, AND CHIEF EXECUTIVE OFFICER

photo of Karen Reeves, MD

PRESIDENT AND CHIEF MEDICAL OFFICER

photo of Jay Mohr

CHIEF OPERATING AND BUSINESS OFFICER, HEAD OF COMMERCIAL DEVELOPMENT

photo of Brian Bartlett

CHIEF ACCOUNTING OFFICER AND INTERIM CHIEF FINANCIAL OFFICER